The Ivy Foundation COVID-19 Translational Research Fund

The Charlottesville-based Ivy Foundation has committed $2 million to accelerate biomedical research focused on COVID-19 at the University of Virginia. The Ivy Foundation COVID-19 Translational Research Fund will support critical research that addresses COVID-19 diagnosis, treatment options, vaccine development and healthcare worker protection needs.

This new expendable fund will be administered through the Office of the Vice President for Research. It will be used to award grants under a framework similar to that of the foundation’s Ivy Biomedical Innovation Fund, which was created in 2008 to support biomedical innovation and translational research projects at UVA that address unmet clinical needs and have a realistic path to delivering improvements in health care.

Request For Applications: 

Now Open!

Request for Applications:  PDF

Please apply by uploading through our internal applications process

Key Dates:

Application Deadline: June 22, 2020 5:00 pm

Awards Announced: July 22, 2020

Award Funding Starts: August 1, 2020

Have a question?

Contact: Cheryl Wagner (Phone: 434.243.1100)

COVID-19 image

Ivy Foundation

Founded in 1999, the Ivy Foundation has accelerated the search for scientific knowledge addressing some of the world’s most urgent medical needs through their commitment to supporting biomedical innovation and translational research at the University of Virginia. The Foundation’s $45 million gift in 2006 funded the Ivy Foundation Translational Research Building, the University’s first facility devoted exclusively to translating basic science discoveries into new treatments and cures that will better the human condition, as well as construction of the Emily Couric Clinical Cancer Center and the Battle Building at the UVA Children's Hospital.  

Since the establishment of the Ivy Biomedical Innovation Fund in 2008, the Foundation has contributed $3,860,00, funding 57 projects in 43 departments and divisions studying a wide variety of disease areas and developing new diagnostic technologies, tools, and treatments for patients. The exponential impact is substantial: as of December 2019, Ivy projects have generated over $15 million in follow-on funding and seven start-up companies have been formed as a direct result of Ivy-funded work.

The Ivy Foundation has also supported two professorships: the Ivy Foundation Pratt Professorship in Morphogenesis and the Ivy Foundation Distinguished Professor of Pediatrics.